TELETRADER News
10/15/2020, 9:16 PM (Source: TeleTrader)
more TeleTrader news

Remdesivir has no major effect on COVID mortality - report

A study ordered by the World Health Organization reportedly concluded that remdesivir, the drug used in treating the COVID-19, has no major effect on increasing patients' chances to survive the disease, as it was previously believed.

According to the Financial Times' report published on Thursday, the results of the WHO's Solidarity trial found out the treatment didn't "substantially affected mortality" or reduced the need for using ventilators. "These remdesivir, hydroxychloroquine, lopinavir and interferon regimens appeared to have little effect on in-hospital mortality," the research reportedly revealed.

Commenting on the report, remdesivir's producer Gilead Sciences Inc. stated that "the emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies validating its clinical benefit."

In recent times, Gilead has signed several agreements worldwide on supplying remdesivir to hospitals after alleged evidence the drug significantly lowers the COVID-19 mortality rate. United States President Donald Trump was also taking the drug as part of his treatment while he had the disease.

Breaking the News / ND